{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:53:57Z","timestamp":1794322437120,"version":"4.9.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are substantial disease and health-related quality-of-life (HRQoL) burdens for many patients with myasthenia gravis (MG), especially for those whose disease symptoms are not well controlled. HRQoL measures such as the Myasthenia Gravis Quality of Life 15-item revised (MG-QOL15r) and EuroQoL 5-Dimensions 5-Levels (EQ-5D-5L) are vital for evaluating the clinical benefit of therapeutic interventions in patients with MG, as they assess the burden of disease and the effectiveness of treatment, as perceived by patients. The phase 3 ADAPT study (NCT03669588) demonstrated that efgartigimod\u2014a novel neonatal Fc receptor inhibitor\u2014was well tolerated and that acetylcholine receptor antibody\u2013positive (AChR-Ab+) participants who received efgartigimod had statistically significant improvements in MG-specific clinical scale scores. The ancillary data reported here, which cover an additional treatment cycle, show that these participants had similar significant improvements in HRQoL measures, the MG-QOL15r and EQ-5D-5L utility and visual analog scales, and that these improvements were maintained in the second treatment cycle. Positive effects on HRQoL were rapid, seen as early as the first week of treatment in both treatment cycles, and maintained for up to 4\u00a0weeks in the follow-up\u2013only portion of treatment cycles. The pattern of improvements in HRQoL paralleled changes in immunoglobulin G level, and correlational analyses show that improvements were consistent across HRQoL measures and with clinical efficacy measures in the ADAPT study. The substantial and durable improvements in HRQoL end points in this study demonstrate the broader benefit of treatment with efgartigimod beyond relief of immediate signs and symptoms of gMG.<\/jats:p>","DOI":"10.1007\/s00415-022-11517-w","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T16:04:41Z","timestamp":1672848281000},"page":"2096-2105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)"],"prefix":"10.1007","volume":"270","author":[{"given":"Francesco","family":"Sacc\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stojan","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn A.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia Z.","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Gelinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Chiroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J. G. M.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"11517_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J (2019) Myasthenia gravis. Nat Rev Dis Primers 5:30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"11517_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/CND.0000000000000257","volume":"20","author":"ANXH Boscoe","year":"2019","unstructured":"Boscoe ANXH, L\u2019Italien GJ, Harris LA, Cutter GR (2019) Impact of refractory myasthenia gravis on health-related quality of life. J Clin Neuromuscul Dis 20:173\u2013181. https:\/\/doi.org\/10.1097\/CND.0000000000000257","journal-title":"J Clin Neuromuscul Dis"},{"key":"11517_CR3","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3389\/fneur.2020.00604","volume":"11","author":"ME Farrugia","year":"2020","unstructured":"Farrugia ME, Goodfellow JA (2020) A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature. Front Neurol 11:604. https:\/\/doi.org\/10.3389\/fneur.2020.00604","journal-title":"Front Neurol"},{"key":"11517_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.553626","volume":"11","author":"P Szczudlik","year":"2020","unstructured":"Szczudlik P, Sobieszczuk E, Szyluk B, Lipowska M, Kubiszewska J, Kostera-Pruszczyk A (2020) Determinants of quality of life in myasthenia gravis patients. Front Neurol 11:553626. https:\/\/doi.org\/10.3389\/fneur.2020.553626","journal-title":"Front Neurol"},{"key":"11517_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12955-015-0298-1","volume":"13","author":"MI Boldingh","year":"2015","unstructured":"Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH, Verschuuren JJ, Tallaksen CM (2015) An up-date on health-related quality of life in myasthenia gravis\u2014results from population based cohorts. Health Qual Life Outcomes 13:115. https:\/\/doi.org\/10.1186\/s12955-015-0298-1","journal-title":"Health Qual Life Outcomes"},{"key":"11517_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5582\/irdr.2019.01121","volume":"8","author":"N Garzon-Orjuela","year":"2019","unstructured":"Garzon-Orjuela N, van der Werf L, Prieto-Pinto LC, Lasalvia P, Castaneda-Cardona C, Rosselli D (2019) Quality of life in refractory generalized myasthenia gravis: a rapid review of the literature. Intractable Rare Dis Res 8:231\u2013238. https:\/\/doi.org\/10.5582\/irdr.2019.01121","journal-title":"Intractable Rare Dis Res"},{"key":"11517_CR7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9184","volume":"12","author":"C Law","year":"2020","unstructured":"Law C, Flaherty CV, Bandyopadhyay S (2020) A review of psychiatric comorbidity in myasthenia gravis. Cureus 12:e9184. https:\/\/doi.org\/10.7759\/cureus.9184","journal-title":"Cureus"},{"key":"11517_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12883-020-01802-4","volume":"20","author":"A Bogdan","year":"2020","unstructured":"Bogdan A, Barnett C, Ali A, AlQwaifly M, Abraham A, Mannan S, Ng E, Bril V (2020) Prospective study of stress, depression and personality in myasthenia gravis relapses. BMC Neurol 20:261. https:\/\/doi.org\/10.1186\/s12883-020-01802-4","journal-title":"BMC Neurol"},{"key":"11517_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206754","volume":"13","author":"A Jeong","year":"2018","unstructured":"Jeong A, Min JH, Kang YK, Kim J, Choi M, Seok JM, Kim BJ (2018) Factors associated with quality of life of people with myasthenia gravis. PLoS ONE 13:e0206754. https:\/\/doi.org\/10.1371\/journal.pone.0206754","journal-title":"PLoS ONE"},{"key":"11517_CR10","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s10072-012-1170-2","volume":"33","author":"IZ Basta","year":"2012","unstructured":"Basta IZ, Pekmezovic TD, Peric SZ, Kisic-Tepavcevic DB, Rakocevic-Stojanovic VM, Stevic ZD, Lavrnic DV (2012) Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia). Neurol Sci 33:1375\u20131381. https:\/\/doi.org\/10.1007\/s10072-012-1170-2","journal-title":"Neurol Sci"},{"key":"11517_CR11","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"11517_CR12","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2022","unstructured":"Lehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L, Stascheit F, Krause M, Hoffmann S, Meisel A (2022) Burden of disease in myasthenia gravis: taking the patient\u02bcs perspective. J Neurol 269:3050\u20133063. https:\/\/doi.org\/10.1007\/s00415-021-10891-1","journal-title":"J Neurol"},{"key":"11517_CR13","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1007\/s00415-021-10759-4","volume":"269","author":"I Bozovic","year":"2022","unstructured":"Bozovic I, Ilic Zivojinovic J, Peric S, Kostic M, Ivanovic V, Lavrnic D, Basta I (2022) Long-term outcome in patients with myasthenia gravis: one decade longitudinal study. J Neurol 269:2039\u20132045. https:\/\/doi.org\/10.1007\/s00415-021-10759-4","journal-title":"J Neurol"},{"key":"11517_CR14","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","volume":"10","author":"KL Gable","year":"2020","unstructured":"Gable KL, Guptill JT (2020) Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis. Front Immunol 10:3052. https:\/\/doi.org\/10.3389\/fimmu.2019.03052","journal-title":"Front Immunol"},{"key":"11517_CR15","doi-asserted-by":"publisher","first-page":"175628641983224","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T (2019) Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord 12:1756286419832242. https:\/\/doi.org\/10.1177\/1756286419832242","journal-title":"Ther Adv Neurol Disord"},{"key":"11517_CR16","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R, Enayetallah A, Beasley KN, Rampal N, Howard JF (2022) Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. https:\/\/doi.org\/10.1056\/EVIDoa2100066","journal-title":"NEJM Evid"},{"key":"11517_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0961203313491849","volume":"22","author":"CWK Bexelius","year":"2013","unstructured":"Bexelius CWK, Skare P, J\u00f6nsson L, Rv V (2013) Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports. Lupus 22:793\u2013801. https:\/\/doi.org\/10.1177\/0961203313491849","journal-title":"Lupus"},{"key":"11517_CR18","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11136-016-1435-y","volume":"26","author":"PW Sullivan","year":"2017","unstructured":"Sullivan PW, Ghushchyan VH, Globe G, Sucher B (2017) Health-related quality of life associated with systemic corticosteroids. Qual Life Res 26:1037\u20131058. https:\/\/doi.org\/10.1007\/s11136-016-1435-y","journal-title":"Qual Life Res"},{"key":"11517_CR19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA (2022) Efgartigimod: first approval. Drugs 82:341\u2013348. https:\/\/doi.org\/10.1007\/s40265-022-01678-3","journal-title":"Drugs"},{"key":"11517_CR20","unstructured":"FDA (2021) Efgartigimod Prescribing Information"},{"key":"11517_CR21","unstructured":"NIH An efficacy and safety study of ARGX-113 in patients with myasthenia gravis who have generalized muscle weakness (ADAPT). Clinicaltrials.gov identifier: NCT03669588. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03669588"},{"key":"11517_CR22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R, ADAPT Investigator Study Group (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526\u2013536. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"11517_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596382","volume":"11","author":"JLS Thomsen","year":"2020","unstructured":"Thomsen JLS, Andersen H (2020) Outcome measures in clinical trials of patients with myasthenia gravis. Front Neurol 11:596382. https:\/\/doi.org\/10.3389\/fneur.2020.596382","journal-title":"Front Neurol"},{"key":"11517_CR24","unstructured":"EuroQol Research Foundation (2019) EQ-5D-5L user guide, 2019"},{"key":"11517_CR25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/ene.1383610.1111\/ene.13836","volume":"26","author":"CBV Barnett","year":"2019","unstructured":"Barnett CBV, Bayoumi AM (2019) EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis. Eur J Neurol 26:452\u2013459. https:\/\/doi.org\/10.1111\/ene.13836","journal-title":"Eur J Neurol"},{"key":"11517_CR26","first-page":"21","volume":"6","author":"JJFS McGough","year":"2009","unstructured":"McGough JJFS (2009) Estimating the size of treatment effects: moving beyond p values. Psychiatry (Edgmont) 6:21\u201329. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2791668\/","journal-title":"Psychiatry (Edgmont)"},{"key":"11517_CR27","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","volume":"74","author":"TM Burns","year":"2010","unstructured":"Burns TM, Conaway M, Sanders DB, Composite MG, MG-QOL15 Study Group (2010) The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 74:1434\u20131440. https:\/\/doi.org\/10.1212\/WNL.0b013e3181dc1b1e","journal-title":"Neurology"},{"key":"11517_CR28","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/mus.25198","volume":"54","author":"TMSR Burns","year":"2016","unstructured":"Burns TMSR, Utsugisawa K, Gwathmey KG, Joshi A, Jones S, Bril V et al (2016) International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve 54:1015\u20131022. https:\/\/doi.org\/10.1002\/mus.25198","journal-title":"Muscle Nerve"},{"key":"11517_CR29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","volume":"36","author":"C Barnett","year":"2018","unstructured":"Barnett C, Herbelin L, Dimachkie MM, Barohn RJ (2018) Measuring clinical treatment response in myasthenia gravis. Neurol Clin 36:339\u2013353. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.006","journal-title":"Neurol Clin"},{"key":"11517_CR30","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jval.2016.11.015","volume":"20","author":"NS McClure","year":"2017","unstructured":"McClure NS, Sayah FA, Xie F, Luo N, Johnson JA (2017) Instrument-defined estimates of the minimally important difference for EQ-5D-5L index scores. Value Health 20:644\u2013650. https:\/\/doi.org\/10.1016\/j.jval.2016.11.015","journal-title":"Value Health"},{"key":"11517_CR31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12955-020-01549-z","volume":"18","author":"D Dong","year":"2020","unstructured":"Dong D, Chong MK, Wu Y, Kaminski H, Cutter G, Xu X, Li H, Zhao C, Yin J, Yu S, Zhu J (2020) Gender differences in quality of life among patients with myasthenia gravis in China. Health Qual Life Outcomes 18:296. https:\/\/doi.org\/10.1186\/s12955-020-01549-z","journal-title":"Health Qual Life Outcomes"},{"key":"11517_CR32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/mus.26695","volume":"60","author":"G Cutter","year":"2019","unstructured":"Cutter G, Xin H, Aban I, Burns TM, Allman PH, Farzaneh-Far R, Duda PW, Kaminski HJ (2019) Cross-sectional analysis of the myasthenia gravis patient registry: disability and treatment. Muscle Nerve 60:707\u2013715. https:\/\/doi.org\/10.1002\/mus.26695","journal-title":"Muscle Nerve"},{"key":"11517_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11082189","author":"L Diez Porras","year":"2022","unstructured":"Diez Porras L, Homedes C, Alberti MA, Velez Santamaria V, Casasnovas C (2022) Quality of life in myasthenia gravis and correlation of MG-QOL15 with other functional scales. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11082189","journal-title":"J Clin Med"},{"key":"11517_CR34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","volume":"77","author":"JF Howard Jr","year":"2020","unstructured":"Howard JF Jr, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ, Zilucoplan MGSG, Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar MG, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib AA, Mathew V, Mozaffar T, Hinton JL, Hewitt W, Barnett D, Sullivan P, Ho D, Howard JF Jr, Traub RE, Chopra M, Kaminski HJ, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatri B, Lindman E, Olapo T, Sershon LM, Lisak RP, Bernitsas E, Jia K, Malik R, Lewis-Collins TD, Nicolle M, Nowak RJ, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe GI, Silvestri N, Patrick K, Zakalik K, Duda PW, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M (2020) Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol 77:582\u2013592. https:\/\/doi.org\/10.1001\/jamaneurol.2019.5125","journal-title":"JAMA Neurol"},{"key":"11517_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120268","volume":"437","author":"D Gelinas","year":"2022","unstructured":"Gelinas D, Parvin-Nejad S, Phillips G, Cole C, Hughes T, Silvestri N, Govindarajan R, Jefferson M, Campbell J, Burnett H (2022) The humanistic burden of myasthenia gravis: a systematic literature review. J Neurol Sci 437:120268. https:\/\/doi.org\/10.1016\/j.jns.2022.120268","journal-title":"J Neurol Sci"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11517-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11517-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11517-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T01:51:29Z","timestamp":1679881889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11517-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["11517"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11517-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"25 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by argenx SE, the manufacturer of efgartigimod alfa, which is approved for use in patients with AChR-Ab+\u2009generalized myasthenia gravis by the US Food and Drug Administration. Sihui Zhao, PhD; Deborah Gelinas, MD; Cynthia Z. Qi; Silvia Chiroli, MD; and Glenn Phillips, PhD, are employees of argenx. Silvia Chiroli, MD, is a stock shareholder in addition to being an employee of argenx. Francesco Sacc\u00e0, MD, has received honoraria for public speaking from Alexion, Biogen, Mylan, Novartis, Roche, Sanofi, and Teva; served on advisory boards for Alexion, Almirall, argenx, AveXis, Biogen, Forward Pharma, Lexeo Therapeutics, Merck, Novartis, Roche, Sanofi, and Takeda; and served as clinical trial principal investigator for Alexion, argenx, Novartis, Prilenia, and Sanofi. Carolina Barnett, MD, PhD, has received grant support from the US Department of Defense, US National Institutes of Health, Muscular Dystrophy Canada, MGNet, Grifols, and Octapharma. She has participated in advisory boards for Alexion, Sanofi, and argenx and been a consultant for CSL, Alexion, and argenx. Jan J.G.M. Verschuuren, MD, has received grant support from the Prinses Beatrix Spierfonds, Health Holland and participated in consultancies for argenx, Alexion, Ra Pharmaceuticals, and NMD Pharma. Reimbursements were received by the Leiden University Medical Centre. He is co-inventor on patent applications based on MuSK-related research. He is a member of the European Reference Network for Rare Neuromuscular Diseases. Stojan Peric, MD, PhD, served as site principal investigator for MG clinical trials sponsored by argenx, Ra\/UCB, and Takeda\/Millennium and is a consultant for argenx. Tuan Vu, MD, served as site principal investigator for MG clinical trials sponsored by Alexion, argenx, Ra\/UCB, Horizon\/Viela Bio, Janssen\/Momenta, Regeneron, and Cartesian Therapeutics and is a consultant for UCB, Alexion, and argenx.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}